FEDERAL COURT OF AUSTRALIA
Eli Lilly and Company v Apotex Pty Ltd [2014] FCA 381
Citation: Eli Lilly and Company v Apotex Pty Ltd [2014] FCA 381 Parties: ELI LILLY AND COMPANY and ELI LILLY AUSTRALIA PTY LIMITED (ACN 000 233 992) v APOTEX PTY LTD (ACN 096 916 148) and APOTEX PTY LTD (ACN 096 916 148) v ELI LILLY AND COMPANY File number: NSD 622 of 2012 Judge: NICHOLAS J Date of judgment: 10 April 2014 Legislation: Evidence Act1995 (Cth) s 192A
Federal Court Rules 2011 (Cth) r 34.50Date of hearing: 4 April 2014 Date of publication of reasons: 16 April 2014 Place: Sydney Division: GENERAL DIVISION Category: No catchwords Number of paragraphs: 11 Counsel for the Applicants: Mr AR Lang Solicitor for the Applicants: Wrays Lawyers Counsel for the Respondent: Mr DK Catterns QC Solicitor for the Respondent: Herbert Smith Freehills
IN THE FEDERAL COURT OF AUSTRALIA
NEW SOUTH WALES DISTRICT REGISTRY
GENERAL DIVISION
NSD 622 of 2012
BETWEEN: ELI LILLY AND COMPANY
First ApplicantELI LILLY AUSTRALIA PTY LIMITED (ACN 000 233 992)
Second ApplicantAND: APOTEX PTY LTD (ACN 096 916 148)
RespondentAND BETWEEN: APOTEX PTY LTD (ACN 096 916 148)
Cross-ClaimantAND: ELI LILLY AND COMPANY
Cross-Respondent
JUDGE:
NICHOLAS J
DATE OF ORDER:
10 APRIL 2014
WHERE MADE:
SYDNEY
THE COURT ORDERS THAT:
1.Leave is given to the applicants pursuant to rule 34.50 to rely upon the evidence of the experiments referred to in section F9 and section G of the affidavit of Shen Yung Luk sworn 10 March 2014 (Dr Luk’s evidence).
2.Order 1 is made without prejudice to the respondent’s right to raise any other objection to the admissibility of Dr Luk’s evidence apart from that which was taken in reliance upon rule 34.50.
3.The costs of both interlocutory applications are to be the respondent’s costs in the proceeding.
Note:Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.
IN THE FEDERAL COURT OF AUSTRALIA
NEW SOUTH WALES DISTRICT REGISTRY
GENERAL DIVISION
NSD 622 of 2012
BETWEEN: ELI LILLY AND COMPANY
First ApplicantELI LILLY AUSTRALIA PTY LIMITED (ACN 000 233 992)
Second ApplicantAND: APOTEX PTY LTD (ACN 096 916 148)
RespondentAND BETWEEN: APOTEX PTY LTD (ACN 096 916 148)
Cross-ClaimantAND: ELI LILLY AND COMPANY
Cross-Respondent
JUDGE:
NICHOLAS J
DATE:
10 APRIL 2014
PLACE:
SYDNEY
REASONS FOR JUDGMENT
The substantive proceeding involves a claim by the applicant for patent infringement. The patent in suit is the same patent that was referred to in Eli Lilly and Company v Generic Health Pty Ltd [2013] FCA 1254. Both proceedings are fixed for hearing commencing on 2 June 2014.
A key issue in the infringement case concerns the size of raloxifene particles in the respondent’s tableted products. Considerable time and effort has been spent by the parties over many months attempting to agree upon an appropriate protocol that would form the basis for experimental evidence directed to that issue. The…
Keep reading for free
Create a free CaseChat account to read Eli Lilly and Company v Apotex Pty Ltd and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2014] FCA 381
- Decision Date
CaseChat Overview and Summary
Orders
Orders of the court
Background
Background to the litigation
Evidence
Evidence Before The Court
Decision
Reasons for decision
Ratio Decidendi